

GlaxoSmithKline Pharmaceuticals Limited GSK House, Dr. Annie Besant Road,

Worli, Mumbai - 400 030 Tel No: +91 22 2495 9595 Fax No: +91 22 2495 9494

Web: www.gsk-india.com Email: askus@gsk.com

1st January 2024

To,

BSE LIMITED

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Phiroze Jeejeebhoy Towers Dalal Street Mumbai - 400001 Exchange Plaza, 5th Floor, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (East) Mumbai - 400051

Dear Sir,

Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject, we would like to inform you that the Company has received an Order dated 29 December 2023 for period FY 2017-18 to 2021-22 from Telangana Central GST authorities, raising total demand of Rs.1,07,16,991 in Telangana State. The relevant details to be is disclosed is as under:

Sr no	Particulars	Details
1	Name of the authority	Joint Commissioner, Central Goods & Services Tax and Central Excise, Medchal Commissionerate
2	Nature and details of the action(s) taken, initiated or order(s) passed	Order dated 29 December 2023 passed under Section 73 & 74 of CGST Act, 2017 for Tax of Rs.91,76,555, Interest Not quantified and Penalty of Rs.15,40,436/-, aggregating to demand of Rs.1,07,16,991
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	31 December 2023
4	Details of violation(s) / contravention(s) committed or alleged to be committed	The officer has disallowed certain GST credit and raised GST demand for FY 2017-18 to 2021-22, largely on account of credit notes issued to customers and difference in GST credit mismatch between Company's GST returns vis-àvis details reported by suppliers in their GST returns.
5	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	No impact on GSK. The Company believes that the said demand is not maintainable and in the process of preferring to file an Appeal against the said Order

Kindly take the same on the record.

Thanking you,

Yours faithfully

For GlaxoSmithKline Pharmaceuticals Limited

Ajay Nadkarni Vice President – Administration, Real Estate & Company Secretary

CIN: L24239MH1924PLC001151